LY2608204 HCl, an investigational drug candidate, is a novel and potent activator of glucokinase (GK) with EC50 of 42 nM. It activates glucokinase (GK) and has shown the novel and potent stimulant of glucokinase (GK) with the EC50 value of 42nM at lower glucose concentrations. In addition, LY2608204 has been reported to activate glucose metabolism with the EC50 value of 579nM in rat insulinoma INS1-E cell lines. Apart from these, LY2608204 has been revealed to lower plasma glucose in a dose-dependent fashion at the levels of fasted and postprandial. LY-2608204 entered clinical trials in 2010 for treat Patients With Type 2 Diabetes.

纯度：≥98%